NCT05380947View on ClinicalTrials.gov

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions
Healthy
Interventions
DRUG

BI 1810631 - trial formulation 1 (TF1)

BI 1810631 - trial formulation 1 (TF1)

DRUG

BI 1810631 - new formulation (NF)

BI 1810631 - new formulation (NF)

DRUG

Rabeprazole sodium

Rabeprazole sodium

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY